ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ABBV-444

A development code.

Its studies are mostly in Dry Eye Syndromes, led by AbbVie.

Furthest: phase 3, since May 24, 20232 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie20 open or runningphase 3since May 24, 2023May 24, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 24, 2023First study: phase 3 study in Dry Eye SyndromesFirst studyNCT05878067 · 40 enrolled · United States
  2. Dec 8, 2025Phase 3 study in Dry Eye SyndromesNCT07284381 · 261 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07284381Dry Eye Syndromes · United States3CompletedAug 21, 2026261
NCT05878067Dry Eye Syndromes · United States3CompletedOct 6, 202340

How it is read

Names in the registry

  • “ABBV-444”, 2 entries

Codes read as this program: ABBV444.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ABBV-444 (AbbVie): development program | ClinicalTrials.gg